KR20140104419A - Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 - Google Patents

Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 Download PDF

Info

Publication number
KR20140104419A
KR20140104419A KR1020147014013A KR20147014013A KR20140104419A KR 20140104419 A KR20140104419 A KR 20140104419A KR 1020147014013 A KR1020147014013 A KR 1020147014013A KR 20147014013 A KR20147014013 A KR 20147014013A KR 20140104419 A KR20140104419 A KR 20140104419A
Authority
KR
South Korea
Prior art keywords
patient
cancer
egfr inhibitor
egfr
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147014013A
Other languages
English (en)
Korean (ko)
Inventor
토마스 리오 프리오
피에르 로랑 - 푸이그
산드린 임베우드
Original Assignee
인테그라겐
아시스땅스 퍼블리끄-오삐또 드 빠리
위니베르시떼 파리 데카르트
쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스)
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인테그라겐, 아시스땅스 퍼블리끄-오삐또 드 빠리, 위니베르시떼 파리 데카르트, 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스), 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) filed Critical 인테그라겐
Publication of KR20140104419A publication Critical patent/KR20140104419A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147014013A 2011-11-25 2012-11-23 Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 Ceased KR20140104419A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11306568.4 2011-11-25
EP11306568 2011-11-25
EP12306042.8 2012-08-31
EP12306042 2012-08-31
PCT/EP2012/073535 WO2013076282A1 (en) 2011-11-25 2012-11-23 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (1)

Publication Number Publication Date
KR20140104419A true KR20140104419A (ko) 2014-08-28

Family

ID=47297187

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014013A Ceased KR20140104419A (ko) 2011-11-25 2012-11-23 Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법

Country Status (10)

Country Link
US (1) US10400284B2 (enExample)
EP (1) EP2783017B1 (enExample)
JP (1) JP6342329B2 (enExample)
KR (1) KR20140104419A (enExample)
CN (1) CN104160038B (enExample)
AU (1) AU2012342397B2 (enExample)
BR (1) BR112014012495A2 (enExample)
CA (1) CA2856594A1 (enExample)
MX (1) MX2014006182A (enExample)
WO (1) WO2013076282A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075662A1 (ko) * 2019-10-18 2021-04-22 지니너스 주식회사 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074530A1 (en) * 2013-11-26 2016-10-05 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
KR101622454B1 (ko) 2014-03-04 2016-05-18 연세대학교 산학협력단 Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커
ES2823756T3 (es) * 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
EP3000895A1 (en) * 2014-09-26 2016-03-30 Integragen A method for predicting responsiveness to a treatment with an EGFR inhibitor
CN107850599B (zh) * 2015-07-23 2021-02-09 新加坡国立大学 Wbp2与her2作为共预后因子对患者分层以进行治疗
WO2017187937A1 (ja) * 2016-04-28 2017-11-02 デンカ株式会社 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法
JP7564122B2 (ja) * 2019-03-29 2024-10-08 ラクテン・メディカル，インコーポレイテッド 光免疫療法のための方法および関連バイオマーカー
CN111798918A (zh) * 2020-05-28 2020-10-20 中山大学孙逸仙纪念医院 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法
CN111863159B (zh) * 2020-06-01 2022-02-25 中山大学孙逸仙纪念医院 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法
JP2025507824A (ja) * 2022-03-01 2025-03-21 クラウン バイオサイエンス （スーチョウ） インコーポレイテッド がん患者におけるセツキシマブ感受性を決定するための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523216C (zh) 2001-03-02 2009-08-05 匹兹堡大学 Pcr方法
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
US20120095030A1 (en) * 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
EP2521555B1 (en) * 2009-11-24 2016-09-28 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
AU2011246976B2 (en) * 2010-04-29 2016-01-28 Allarity Therapeutics Europe ApS Methods and devices for predicting treatment efficacy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075662A1 (ko) * 2019-10-18 2021-04-22 지니너스 주식회사 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물

Also Published As

Publication number Publication date
CN104160038A (zh) 2014-11-19
MX2014006182A (es) 2014-12-08
AU2012342397A1 (en) 2014-06-12
JP6342329B2 (ja) 2018-06-13
US10400284B2 (en) 2019-09-03
BR112014012495A2 (pt) 2017-06-06
CN104160038B (zh) 2018-06-12
EP2783017A1 (en) 2014-10-01
JP2014533960A (ja) 2014-12-18
AU2012342397B2 (en) 2018-04-05
CA2856594A1 (en) 2013-05-30
US20140370029A1 (en) 2014-12-18
EP2783017B1 (en) 2018-12-26
WO2013076282A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
AU2012342397B2 (en) A method for predicting responsiveness to a treatment with an EGFR inhibitor
US12077803B2 (en) MicroRNAs as biomarkers for endometriosis
EP2152900A2 (en) Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US20160376661A1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
JP2019537436A (ja) 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム
EP3198028B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
US20150344961A1 (en) Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
KR20100037636A (ko) Ｅｇｆｒ 억제제 치료에 대한 예측 마커
AU2008286406A1 (en) Predictive markers for EGFR inhibitor treatment
HK40011172A (en) Micrornas as biomarkers for endometriosis
HK40011172B (en) Micrornas as biomarkers for endometriosis
KR20100037641A (ko) Ｅｇｆｒ 저해제 처리에 대한 예측성 마커

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171026

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190214

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I